Evidence map›Paper›PMID 38887232›Full record

ArticleFrontiers in oncology2024

Anxiety and depression in patients with non-site-specific cancer symptoms: data from a rapid diagnostic clinic.

Maria J Monroy-Iglesias, Beth Russell, Sabine Martin, Louis Fox, Charlotte Moss, Flaminia Bruno, Juliet Millwaters, Lindsay Steward, Colette Murtagh, Carlos Cargaleiro and 11 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Maria J Monroy-IglesiasTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Beth RussellTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Sabine MartinMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Louis FoxTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Charlotte MossTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Flaminia BrunoMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Juliet MillwatersMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Lindsay StewardMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Colette MurtaghMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Carlos CargaleiroMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Darren BaterMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Grace LavelleKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, United Kingdom.
Anna SimpsonKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, United Kingdom.
Jemima OnihKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, United Kingdom.
Anna HaireTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Clare ReederMacmillan Psychological Support (MAPS) Team, Lewisham and Greenwich NHS Trust, London, United Kingdom.
Geraint JonesSouth East London Cancer Alliance, London, United Kingdom.
Sue SmithDimbleby Cancer Care, Guy's Cancer Centre, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.
Aida SantaolallaTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Mieke Van HemelrijckTranslational Oncology and Urology Research, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom.
Saoirse DollyMedical Oncology, Guy's and St Thomas' National Health System (NHS) Foundation Trust, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rapid diagnostic clinics (RDCs) provide a streamlined holistic pathway for patients presenting with non-site specific (NSS) symptoms concerning of malignancy. The current study aimed to: 1) assess the prevalence of anxiety and depression, and 2) identify a combination of patient characteristics and symptoms associated with severe anxiety and depression at Guy's and St Thomas' Foundation Trust (GSTT) RDC in Southeast London. Additionally, we compared standard statistical methods with machine learning algorithms for predicting severe anxiety and depression. Methods: Patients seen at GSTT RDC between June 2019 and January 2023 completed the General Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-8) questionnaires, at baseline. We used logistic regression (LR) and 2 machine learning (ML) algorithms (random forest (RF), support vector machine (SVM)) to predict risk of severe anxiety and severe depression. The models were constructed using a set of sociodemographic and clinical variables. Results: A total of 1734 patients completed GAD-7 and PHQ-8 questionnaires. Of these, the mean age was 59 years (Standard Deviation: 15.5), and 61.5% (n:1067) were female. Prevalence of severe anxiety (GAD-7 score ≥15) was 13.8% and severe depression (PHQ-8 score≥20) was 9.3%. LR showed that a combination of previous mental health condition (PMH, Adjusted Odds Rario (AOR) 3.28; 95% confidence interval (CI) 2.36-4.56), symptom duration >6 months (AOR 2.20; 95%CI 1.28-3.77), weight loss (AOR 1.88; 95% CI 1.36-2.61), progressive pain (AOR 1.71; 95%CI 1.26-2.32), and fatigue (AOR 1.36; 95%CI 1.01-1.84), was positively associated with severe anxiety. Likewise, a combination PMH condition (AOR 3.95; 95%CI 2.17-5.75), fatigue (AOR 2.11; 95%CI 1.47-3.01), symptom duration >6 months (AOR 1.98; 95%CI 1.06-3.68), weight loss (AOR 1.66; 95%CI 1.13-2.44), and progressive pain (AOR 1.50; 95%CI 1.04-2.16), was positively associated with severe depression. LR and SVM had highest accuracy levels for severe anxiety (LR: 86%, SVM: 85%) and severe depression (SVM: 89%, LR: 86%). Conclusion: High prevalence of severe anxiety and severe depression was found. PMH, fatigue, weight loss, progressive pain, and symptoms >6 months emerged as combined risk factors for both these psychological comorbidities. RDCs offer an opportunity to alleviate distress in patients with concerning symptoms by expediting diagnostic evaluations.

Indexed as

anxietycancerdepressionmachine learningnon-site specificstandard statistics

Identifiers

PMID38887232
PMCPMC11180766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.